Inhibikase Therapeutics earnings release, May 12, 2026

Inhibikase Therapeutics, Inc. (IKT) · Form 8-K, Item 2.02 · Filed · SEC filing

Inhibikase Therapeutics Announces First Quarter 2026

Financial Results and Highlights Recent Activity

WILMINGTON, Del., May 12, 2026 — Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or

“Company”), a clinical-stage pharmaceutical company developing

IKT-001 for Pulmonary Arterial Hypertension (“PAH”), today reported financial results for the quarter ended March 31,

2026, and highlighted recent developments.

“We were excited to enroll the first patient in our registrational

IMPROVE-PAH study last month, and are very pleased with our early progress obtaining country regulatory approvals to support initiation of clinical sites, including being one of the first companies to successfully take advantage of the new European Medicines Agency

FAST-EU

(Facilitating and Accelerating Strategic Trials in the European Union) initiative to accelerate multinational clinical trials,” said Mark Iwicki, Chief Executive Officer of Inhibikase. “With the recent approvals obtained in the first 16 countries worldwide, Inhibikase is well-positioned to initiate clinical site activations and seek to advance enrollment of

IMPROVE-PAH.

Later this week, we also look forward to the first of two new presentations of Phase 1 and pre-clinical studies of

IKT-001 at the

American Thoracic Society International Conference, to be held in Orlando, Florida.”

Recent Developments¹

Upcoming Presentations

Financial Results

Cash Position:

As of March 31, 2026, cash, cash equivalents and marketable securities were $170.4 million.

Net Loss:

Net loss for the quarter ended March 31, 2026, was $16.4 million, or $0.10 per share, compared to a net loss of $13.7 million, or $0.15 per share in the quarter ended March 31, 2025.

R&D Expenses:

Research and development expenses were $10.8 million for the quarter ended March 31, 2026, compared to $10.5 million for the quarter ended March 31, 2025, which included a one-time

(non-cash) charge of

$7.4 million for the acquired IPR&D related to the CorHepta acquisition.

SG&A Expenses:

Selling, general and administrative expenses for the quarter ended March 31, 2026 were $7.4 million, compared to $5.2 million for the quarter ended March 31, 2025.

About

Inhibikase (www.inhibikase.com)

Inhibikase Therapeutics, Inc. (Nasdaq: IKT) is a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases, namely, Pulmonary Arterial Hypertension (“PAH”), in which aberrant signaling through type III receptor tyrosine kinases, including platelet derived growth factor receptors and a stem cell factor receptor, known as

“c-Kit,” has been implicated. Our lead product candidate is

IKT-001, a prodrug of imatinib mesylate (“imatinib”), for PAH which is an orphan indication. Imatinib was first approved in the United States in 2001 for various cancers and blood disorders and, following more than 20 years of clinical use, has a well-characterized safety profile with the first reported use of imatinib in PAH occurring in 2005. PAH is a progressive, life-threatening disease characterized by pulmonary vascular remodeling and elevated pulmonary vascular resistance that affects approximately 50,000 Americans. Our single pivotal Phase 3 clinical study in PAH in approximately 180 sites around the world, named

IMPROVE-PAH

(

I

KT-001 for

M easuring

P ulmonary Vascular

R esistance and

O utcome

V ariables in a Phase 3

E valuation of

PAH), is actively enrolling patients.²

Social Media Disclaimer

Investors and others should note that the Company announces material financial information to investors using its investor relations website, press releases,

SEC filings and public conference calls and webcasts. The Company intends to also use LinkedIn as a means of disclosing information about the Company, its services and other matters and for complying with its disclosure obligations under

Regulation FD.

Financial statements

Income Statement

Three months ended March 31, — (Unaudited)

Three months ended March 31, – 2026Three months ended March 31, – 2025
Costs and expenses:Research and development10,839,15010,513,579
Costs and expenses:Selling, general and administrative7,376,1235,249,291
Costs and expenses:Change in fair value contingent consideration-373,354-1,164,864
Costs and expenses:Total costs and expenses17,841,91914,598,006
Costs and expenses:Loss from operations-17,841,919-14,598,006
Costs and expenses:Other income1,461,079919,271
Costs and expenses:Net loss-16,380,840-13,678,735
Other comprehensive income (loss), net of taxUnrealized gain (loss) on marketable securities-48,09536,281
Other comprehensive income (loss), net of taxComprehensive loss-16,428,935-13,642,454
Other comprehensive income (loss), net of taxNet loss per share – basic and diluted-0.1-0.15
Other comprehensive income (loss), net of taxWeighted-average number of shares – basic and diluted172,306,93289,537,171

Balance Sheet

March 31, 2026 — (Unaudited)

March 31, 2026December 31, 2025
Current assets:Cash and cash equivalents49,573,510139,220,208
Current assets:Marketable securities120,795,23539,543,820
Current assets:Prepaid research and development514,9101,001,993
Current assets:Prepaid expenses and other current assets1,292,813343,374
Current assets:Total current assets172,176,468180,109,395
Current assets:Prepaid research and development, noncurrent1,000,0001,000,000
Current assets:Other assets155,75995,121
Current assets:Total assets173,332,227181,204,516
Current liabilities:Accounts payable1,587,3051,158,054
Current liabilities:Accrued expenses and other current liabilities4,124,6544,081,282
Current liabilities:Contingent consideration liability3,061,501
Current liabilities:Total current liabilities5,711,9598,300,837
Current liabilities:Total liabilities5,711,9598,300,837
Stockholders’ equity:Common stock, $0.001 par value; 500,000,000 shares authorized; 132,032,636 and 131,691,237 shares issued and outstanding (including 0 and 4,149,252 contingently issuable shares - see Note 10) at March 31, 2026 and December 31, 2025, respectively132,032131,691
Stockholders’ equity:Additional paid-in capital326,575,169315,429,986
Stockholders’ equity:Accumulated other comprehensive income (loss)-26,29321,802
Stockholders’ equity:Accumulated deficit-159,060,640-142,679,800
Stockholders’ equity:Total stockholders’ equity167,620,268172,903,679
Stockholders’ equity:Total liabilities and stockholders’ equity173,332,227181,204,516

Cash Flow

Three months ended March 31, — (Unaudited)

Three months ended March 31, – 2026Three months ended March 31, – 2025
Cash flows from operating activitiesNet loss-16,380,840-13,678,735
Adjustments to reconcile net loss to net cash used in operating activities:Depreciation12,654
Adjustments to reconcile net loss to net cash used in operating activities:Stock-based compensation expense5,559,7662,042,196
Adjustments to reconcile net loss to net cash used in operating activities:Write-off of in-process research and development7,357,294
Adjustments to reconcile net loss to net cash used in operating activities:Change in fair value contingent consideration-373,354-1,164,864
Adjustments to reconcile net loss to net cash used in operating activities:Non-cash accretion on marketable securities-814,923
Changes in operating assets and liabilities:Operating lease right-of-use assets32,718
Changes in operating assets and liabilities:Prepaid expenses and other current assets-949,439-211,924
Changes in operating assets and liabilities:Prepaid research and development487,08328,833
Changes in operating assets and liabilities:Other assets-60,638
Changes in operating assets and liabilities:Accounts payable429,251680,824
Changes in operating assets and liabilities:Operating lease liabilities-35,745
Changes in operating assets and liabilities:Accrued expenses and other current liabilities43,372833,219
Changes in operating assets and liabilities:Net cash used in operating activities-12,059,722-4,103,530
Cash flows from investing activitiesPurchases of equipment and improvements-13,399
Cash flows from investing activitiesPurchases of investments - marketable securities-90,584,587
Cash flows from investing activitiesMaturities of investments - marketable securities10,100,00021,506,365
Cash flows from investing activitiesAcquired in-process research and development-438,624
Cash flows from investing activitiesNet cash provided by (used in) investing activities-80,484,58721,054,342
Cash flows from financing activitiesProceeds from issuance of common stock, pre-funded warrants and warrants, net of issuance costs2,897,611
Cash flows from financing activitiesNet cash provided by financing activities2,897,611
Cash flows from financing activitiesNet increase (decrease) in cash and cash equivalents-89,646,69816,950,812
Cash flows from financing activitiesCash and cash equivalents at beginning of period139,220,20856,490,579
Cash flows from financing activitiesCash and cash equivalents at end of period49,573,51073,441,391
Supplemental disclosures of cash flow informationIssuance costs85,000$—
Non-cash investing and financing activitiesContingent consideration$—3,270,579
Non-cash investing and financing activitiesSettlement of contingent consideration liability2,688,147$—
Full release

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking terminology such as “believes,” “expects,” “may,”

“will,” “should,” “anticipates,” “plans,” or similar expressions or the negative of these terms and similar expressions are intended to identify forward-looking statements. These forward-looking statements include, but are not limited to, statements that express the Company’s intentions, beliefs, expectations, strategies, predictions or any other statements related to the potential effects of

IKT-001, the advancement of the Company’s global pivotal Phase 3 clinical study of

IKT-001 in PAH, including the timing, design, and conduct of the

IMPROVE-PAH study and related regulatory submissions, the Company’s ability to obtain additional regulatory approvals for the

IMPROVE-PAH study, the Company’s beliefs regarding the potential advantages of the Phase 3 clinical study of

IKT-001, or future events or conditions. These forward-looking statements are based on Inhibikase’s current expectations and assumptions. Such statements are subject to certain risks and uncertainties, which could cause Inhibikase’s actual results to differ materially from those anticipated by the forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements include our ability to execute a Phase 3 study to evaluate

IKT-001 as a treatment for PAH, as well as such other factors that are included in our periodic reports on Form

10-K and Form

10-Q that we file with the U.S. Securities and Exchange Commission. Any forward-looking statement in this release... (truncated)nformation, future developments or otherwise, except as may be required by any applicable securities laws.

Contacts:

Investor

Relations:

Michael Moyer

LifeSci Advisors mmoyer@lifesciadvisors.com —tables to follow—³

Inhibikase Therapeutics, Inc.

Condensed Consolidated Balance Sheets

(Unaudited)⁴

Inhibikase Therapeutics, Inc.

Condensed Consolidated Statements of Operations and Comprehensive Loss

(Unaudited)

Inhibikase Therapeutics, Inc.

Condensed Consolidated Statements of Cash Flows

(Unaudited)

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Inhibikase Therapeutics earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.